---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-048557"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:35:53.286075+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Esperion appoints John Harlow as Chief Commercial Officer effective Nov 17, 2025

## Summary
- John Harlow appointed CCO; base salary $535,000, target bonus 45%, sign-on bonus $35,000.
- Equity grants: option for 380,000 shares and 424,536 RSUs, vesting over four years.
- Harlow previously CCO at Melinta Therapeutics, where revenue nearly doubled (~85% growth from 2020 to 2024).
- He reports to CEO Sheldon Koenig and joins Esperion's Executive Leadership Team.
- Harlow brings over 20 years of pharma commercial leadership from Melinta, Baudax Bio, Endo, Pfizer, and Novartis.

## SEC filing metadata
- accession: 0001628280-25-048557
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000162828025048557/0001628280-25-048557-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000162828025048557/espr-20251104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-048557
- JSON: https://secwatch.observer/filing/0001628280-25-048557.json
- Plain text: https://secwatch.observer/filing/0001628280-25-048557.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.